INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

Part of paid clinical trials in Albuquerque, New Mexico.

Sponsor
University of New Mexico
Study ID
NCT00276003
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Primary objectives * Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan. Secondary objectives * Assess progression free survival in these patients treated with this regimen. * Assess toxicity of this regimen in this group of patients.

Key Dates

Start date
Aug 31, 2002
Status verified
Dec 2009
Primary completion
Jun 30, 2005
Completion
Aug 31, 2005

Study Design

Enrollment
22 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan. [ Time Frame: 3 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Lovelace Sandia Health Systems Dept of HematologyAlbuquerqueNew Mexico87108-
University of New MexicoAlbuquerqueNew Mexico87131-

Find similar trials in Albuquerque, NM

By research site
Lovelace Sandia Health Systems Dept of Hematology· Albuquerque, NMUniversity of New Mexico· Albuquerque, NM

Related Studies